See more : Blue Dolphin Energy Company (BDCO) Income Statement Analysis – Financial Results
Complete financial analysis of Neuronetics, Inc. (STIM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neuronetics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Kalera Public Limited Company (KALWW) Income Statement Analysis – Financial Results
- GPT Healthcare Limited (GPTHEALTH.NS) Income Statement Analysis – Financial Results
- Mercari, Inc. (MCARY) Income Statement Analysis – Financial Results
- Amrutanjan Health Care Limited (AMRUTANJAN.BO) Income Statement Analysis – Financial Results
- Rolex Rings Limited (ROLEXRINGS.BO) Income Statement Analysis – Financial Results
Neuronetics, Inc. (STIM)
About Neuronetics, Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 71.35M | 65.21M | 55.31M | 49.24M | 62.66M | 52.78M | 40.43M | 34.23M |
Cost of Revenue | 19.64M | 15.48M | 11.65M | 11.55M | 15.39M | 12.45M | 9.63M | 6.62M |
Gross Profit | 51.71M | 49.72M | 43.66M | 37.69M | 47.27M | 40.33M | 30.80M | 27.61M |
Gross Profit Ratio | 72.47% | 76.26% | 78.93% | 76.54% | 75.44% | 76.42% | 76.18% | 80.65% |
Research & Development | 9.52M | 9.34M | 7.92M | 9.20M | 13.75M | 8.23M | 7.94M | 8.22M |
General & Administrative | 25.43M | 25.52M | 25.55M | 18.24M | 17.46M | 13.67M | 8.57M | 6.93M |
Selling & Marketing | 47.32M | 49.98M | 37.75M | 32.56M | 42.99M | 38.26M | 27.90M | 21.79M |
SG&A | 72.74M | 75.50M | 63.30M | 50.80M | 60.45M | 51.93M | 36.47M | 28.72M |
Other Expenses | 0.00 | 2.20M | 390.00K | 302.00K | 1.57M | -575.00K | 357.00K | -62.00K |
Operating Expenses | 82.26M | 84.83M | 71.22M | 60.00M | 74.20M | 60.16M | 44.41M | 36.94M |
Cost & Expenses | 101.90M | 100.32M | 82.88M | 71.55M | 89.59M | 72.61M | 54.04M | 43.57M |
Interest Income | 24.00K | 2.05M | 3.63M | 4.22M | 2.11M | 0.00 | 0.00 | 0.00 |
Interest Expense | 5.42M | 4.25M | 4.02M | 4.52M | 3.69M | 3.69M | 2.81M | 1.84M |
Depreciation & Amortization | 2.01M | 1.65M | 1.06M | 941.00K | 1.07M | 882.00K | 673.00K | 673.00K |
EBITDA | -22.76M | -31.26M | -26.55M | -21.07M | -26.93M | -19.53M | -12.58M | -8.73M |
EBITDA Ratio | -31.90% | -47.94% | -47.21% | -42.78% | -38.77% | -37.00% | -31.30% | -25.49% |
Operating Income | -30.55M | -35.11M | -27.56M | -22.31M | -26.93M | -19.83M | -13.61M | -9.34M |
Operating Income Ratio | -42.82% | -53.85% | -49.83% | -45.30% | -42.98% | -37.58% | -33.66% | -27.28% |
Total Other Income/Expenses | 365.00K | -2.05M | -3.63M | -5.14M | -2.11M | -4.26M | -2.45M | -1.90M |
Income Before Tax | -30.19M | -37.16M | -31.19M | -27.45M | -29.04M | -24.10M | -16.06M | -11.23M |
Income Before Tax Ratio | -42.31% | -56.99% | -56.39% | -55.75% | -46.35% | -45.66% | -39.72% | -32.82% |
Income Tax Expense | -24.00K | 2.05M | 4.41M | 4.82M | 5.26M | -575.00K | 3.17M | 1.77M |
Net Income | -30.19M | -39.21M | -35.60M | -32.28M | -34.30M | -24.10M | -16.06M | -11.23M |
Net Income Ratio | -42.31% | -60.13% | -64.37% | -65.55% | -54.74% | -45.66% | -39.72% | -32.82% |
EPS | -1.05 | -1.46 | -1.40 | -1.71 | -1.87 | -2.69 | -1.43K | -1.00K |
EPS Diluted | -1.05 | -1.46 | -1.40 | -1.71 | -1.87 | -2.69 | -1.43K | -1.00K |
Weighted Avg Shares Out | 28.66M | 26.90M | 25.48M | 18.84M | 18.38M | 8.95M | 11.22K | 11.22K |
Weighted Avg Shares Out (Dil) | 28.66M | 26.90M | 25.48M | 18.84M | 18.38M | 8.95M | 11.22K | 11.22K |
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans
NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript
Neuronetics to Present at the JMP Securities Life Sciences Conference
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
Cannell Capital Now Owns 11.03% of Neuronetics
Source: https://incomestatements.info
Category: Stock Reports